In a deal that now feels like a biotech version of ‘Moneyball,’ Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer.
In a deal that now feels like a biotech version of ‘Moneyball,’ Roivant announced it was selling an asset that only 11 months ago it got for free from Pfizer.